Max Ahn, MD
Urology · Wynnewood, PANPI 1548224462
Payments from drug & device makers
Across 120 payments — averaging $80.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Procept Biorobotics Corporation$2K
- Dendreon Pharmaceuticals LLC$971
- Boston Scientific$351
- Johnson & Johnson$300
- Teleflex LLC$259
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$2,10022%
- Travel & lodging$3,34435%
- Food & beverage$4,21644%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 14 | $4,093 |
| Procept Biorobotics Corporation | 15 | $1,950 |
| Dendreon Pharmaceuticals LLC | 10 | $971 |
| Boston Scientific | 6 | $351 |
| Johnson & Johnson | 12 | $300 |
| Teleflex LLC | 3 | $259 |
| AbbVie | 10 | $224 |
| Bayer | 6 | $142 |
| Pfizer | 6 | $129 |
| Immunitybio, Inc. | 1 | $119 |
| Davol Inc. | 1 | $108 |
| Cook Medical LLC | 2 | $105 |
| Ferring Pharmaceuticals Inc. | 1 | $98 |
| Janssen Scientific Affairs, LLC | 1 | $92 |
| Tolmar, Inc. | 4 | $88 |
| Medtronic | 2 | $84 |
| Axonics, Inc. | 3 | $62 |
| Sumitomo Pharma America, Inc. | 3 | $54 |
| Merck | 2 | $51 |
| Calyxo, Inc. | 2 | $45 |
| Astellas Pharma US Inc | 2 | $44 |
| Urogen Pharma, Inc. | 2 | $40 |
| Olympus America Inc. | 2 | $37 |
| Smith+Nephew | 1 | $32 |
| Novartis | 1 | $31 |
| Profound Medical Corp. | 1 | $28 |
| Tolmar Pharmaceuticals, Inc. | 1 | $27 |
| Telix Pharmaceuticals | 1 | $22 |
| AstraZeneca | 1 | $22 |
| Conmed Corporation | 1 | $21 |
| Tempus AI, Inc | 1 | $18 |
| 180 Medical, Inc. | 1 | $18 |
| Mimedx Group, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,843
- AquaBeam Robotic System$1,456
- PROVENGE$714
- LithoVue$263
- UroLift System$127
- ANKTIVA$119
- ARISTA AH FLEXITIP$108
How this compares
$9,680 in reported general payments places this provider in the 80th percentile of 596 urology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 44 | $625,585 |
| XtandiEnzalutamide | 32 | $422,996 |
| OrgovyxRelugolix | 88 | $227,480 |
| Abiraterone Acetate | 37 | $186,289 |
| MyrbetriqMirabegron | 140 | $76,155 |
| Tamsulosin Hcl | 911 | $17,822 |
| GemtesaVibegron | 28 | $14,402 |
| Finasteride | 463 | $7,597 |
| Potassium Citrate ErPotassium Citrate | 43 | $7,330 |
| Oxybutynin Chloride ErOxybutynin Chloride | 155 | $4,359 |
| Silodosin | 23 | $3,247 |
| Tolterodine Tartrate ErTolterodine Tartrate | 33 | $3,196 |
| Darifenacin ErDarifenacin Hydrobromide | 11 | $2,519 |
| Testosterone | 48 | $2,301 |
| Solifenacin Succinate | 95 | $2,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $300 | $625,58544 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $44 | $499,151172 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $54 | $241,881116 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $92 | $186,28937 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 596 urology providers in Pennsylvania.
Other urology in Wynnewood
- Gregory McMahonWynnewood$79K
- Laurence BelkoffBala Cynwyd$18.7M
- Paul SieberLancaster$12.6M
- Costas LallasPhiladelphia$3.6M
- John AndersonBethlehem$2.1M
- Jodi MaranchiePittsburgh$1.2M
- Kenneth LessansLancaster$943K
- Stanley MalkowiczPhiladelphia$882K
- Demetrius BagleyPhiladelphia$739K
- Gregory TasianPhiladelphia$645K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.